New pill takes on Hard-to-Treat cancers in first human trial
NCT ID NCT05159700
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests an experimental oral drug called PRJ1-3024 in 39 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PRJ1-3024 (oral capsule)
What this could lead to
If this drug is safe and shows signs of shrinking tumors, it could lead to a new treatment option for people with advanced solid cancers that have stopped responding to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 39 participants. The main goal is safety, not effectiveness. Many drugs fail at this stage, and side effects may be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Christ Hospital
Cincinnati, Ohio, 21073, United States
-
Mays Cancer Center
San Antonio, Texas, 78229, United States
-
NEXT Oncology
Austin, Texas, 73301, United States
-
NEXT Oncology
Fairfax, Virginia, 22031, United States
-
Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando, Florida, 32827, United States
-
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, 80218, United States